drugset / Trial / NCT04901299
Fulvestrant + Neratinib In Breast Cancer
Phase 2
Withdrawn
Massachusetts General Hospital
Celcuity Inc · collabPuma Biotechnology, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative breast cancer. * This research study involves the study drug Neratinib * The standard of care drug Fulvestrant
Timeline
- Start
- 2023-07
- Primary completion
- 2024-07-01
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | — | Oral |
| Background | Fulvestrant | Small molecule | — | Other |